← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Achaogen, Inc.
South San Francisco, CA
$33,449,038
Total funding
6
Grants
Funding over time
peak $14.1M · FY2008–17$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$27,911,610 · 3
DOD$5,537,428 · 3
By mechanism
N01$27,504,506 · 2
—$5,537,428 · 3
R21$407,104 · 1
Investigators at Achaogen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Novel Antimicrobial Resistance Agents$11,330,516
N01 · FY2008 · AI
Development of Novel Antimicrobial Resistance Agents$5,697,418
N01 · FY2010 · AI
Development of Novel Antimicrobial Resistance Agents$5,160,457
N01 · FY2011 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$2,933,817
N01 · FY2016 · AI
DEVELOPMENT OF NOVEM AMINOGLYCODSIDE AGENTS WITH ACTIVITY AGAINST MULTI-DRUG RESISTANT ACINETOBACTER BAUMANNII$2,724,779
· FY2008 · Department of Defense
A FIRST-IN-HUMAN PHASE 1 CLINICAL STUDY OF ACHN-975, A FIRST-IN-CLASS AGENT BEING DEVELOPED FOR THE TREATMENT OF SERIOUS MULTIDRUG-RESISTANT GRAM-NEG$2,499,000
· FY2012 · Department of the Army
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,499,801
N01 · FY2015 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$882,497
N01 · FY2017 · AI
Structure and property driven optimization of fatty acid synthesis inhibitors for$407,104
R21 · FY2014 · AI
DEVELOPMENT OF NAV1.7 ACTIVITY-BLOCKING ANTIBODY FOR ANALGESIA$313,649
· FY2017 · Department of the Army